Vaccines against genital herpes: Progress and limitations

Drugs

Volumn 62, Issue 8, 2002, Pages 1119-1129

  Morrison, Lynda A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; LIVE VACCINE; NUCLEIC ACID;

CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; PERSISTENT VIRUS INFECTION; REVIEW; SEXUAL TRANSMISSION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

ANIMALIA; DNA VIRUSES; SIMPLEXVIRUS;

EID: 0036267363     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262080-00001     Document Type: Review

References (93)

1. A seroepidemiologic survey for the prevalence of herpes simplex virus type 2 infection in the United States
2. Herpes simplex virus type 2 in the United States, 1976 to 1994
3. Epidemiology of genital herpes in Pittsburgh: Serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections
4. A cross-sectional study of herpes simplex virus types I and 2 in college students
5. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations
6. Surveillance report: Disease trends at New Zealand sexually transmitted disease clinics
7. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population
8. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals
9. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe
10. The association between genital ulcer disease and acquisition of HIV infection in homosexual men
11. Herpes simplex virus latency - Associated transcripts is a stable intron
12. Recurrences after oral and genital herpes simplex virus infection: Influence of site of infection and viral type
13. Recurrent genital herpes among women: Symptomatic v. asymptomatic viral shedding
14. Persistence of virus shedding in asymptomatic women after recovery from herpes genitalis
15. Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes
16. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes
17. Risk factors for the sexual transmission of genital herpes
18. Perinatal risk associated with maternal genital herpes simplex virus infection
19. Herpes simplex viruses 1 and 2
20. Herpes simplex virus-2 infection: An emerging disease?
21. Neonatal herpes simplex virus infection in the British Isles
22. Neonatal herpes policy in The Netherlands. Five years after a consensus conference
23. Changing presentation of herpes simplex virus infection in neonates
24. The natural history of herpes simplex virus infection of mother and newborn
25. Predictors of morbidity in neonates with herpes simplex virus infections
26. The efficacy and safety of skinner herpes simplex vaccine towards modulation of herpes genitalis: Report of a prospective double-bind placebo-controled trial
27. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection
28. Clinical studies with herpes simplex virus type 2 Curtis strain vaccine
29. A recombinant glycoprotein vaccine in herpes simplex type 2: Safety and efficacy
30. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine
31. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family
32. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. Two randomized controlled trials
33. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: Protection against challenge with virulent virus
34. Herpes simplex vaccines
35. Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection
36. Evolution of recurrent herpes simplex lesions. An immunohistologic study
37. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes
38. Direct recovery of herpes simplex virus HSV-specific T lymphocyte clones from human recurrent genital HSV-2 lesions
39. Tipping the scales of herpes simplex virus reactivation: The important responses are local
40. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection
41. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions
42. CD8 CTL from genital herpes simplex lesions: Recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells
43. CD4 t-cell responses to herpes simplex virus type 2 major capsid protein VP5: Comparison with responses to tegument and envelope glycoproteins
44. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes
45. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2
46. Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse models
47. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type-2 genital infection in the presence of immune T. cells
48. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: Characterization of the immunoglobulins in vaginal mucus
49. IgG is the mian protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2
50. Immune protection against HSV-2 in B-cell-deficient mice
51. Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice
52. Secretory IgA antibody in cervicovaginal secretions from women with genital infection due to herpes simplex virus
53. Selecting and maintaining a diverse T-cell repertoire
54. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial
55. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
56. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth
57. Herpes simplex viruses
58. Genital herpes vaccine shows limited promise
59. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems
60. Use of herpes simplex virus (HSV) type I ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs
61. DNA vaccines and immunity to herpes simplex virus
62. Protection by minigenes: A novel approach of DNA vaccines
63. DNA immunization against experimental genital herpes simplex virus infection
64. Herpes simplex virus DNA vaccine efficacy: Effect of glycoprotein D plasmid constructs
65. Protective immune correlates can segregate by vaccine type in a murine herpes model system
66. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis
67. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes
68. Tetramer-guided epitope mapping: Rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens
69. HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: Direct detection of immunodominant antigen-responsive cells
70. Live vaccinia virus recombinants expressing herpes simplex virus genes
71. Adenovirus vectors as potential vaccines against herpes simplex virus
72. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells
73. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine
74. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
75. Therapeutic vaccination against HSV-2: Influence of vaccine formulation on immune responses and protection in mice
76. Construction and characterization of a replication-defective HSV-2
77. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection
78. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus 1 vaccine strain
79. DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model
80. Prime-boost immunization with DNA vaccine: Mucosal route of administration changes the rules
81. Herpes simplex virus turns off the TAP to evade host immunity
82. Human herpes simples virus (HSV)-specific CD8+ CTL clones recognize HSV-2 infected fibroblasts after treatment with IFN-γ or when virion host shutoff functions are disabled
83. Inhibition of dendritic cell maturation by herpes simplex virus
84. Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines
85. Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines
86. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4 (+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo
87. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge
88. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands
89. Modulation of the immune response to DNA vaccine by co-delivery-of costimulatory molecules
90. LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: Involvement of CD4+ T cells in protection
91. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
92. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization
93. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract